KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ionis Pharmaceuticals (IONS) Interest Expenses (2016 - 2025)

Ionis Pharmaceuticals has reported Interest Expenses over the past 17 years, most recently at $4.8 million for Q4 2025.

  • Quarterly results put Interest Expenses at $4.8 million for Q4 2025, up 15.2% from a year ago — trailing twelve months through Dec 2025 was $17.3 million (up 1.58% YoY), and the annual figure for FY2025 was $17.3 million, up 1.58%.
  • Interest Expenses for Q4 2025 was $4.8 million at Ionis Pharmaceuticals, up from $4.2 million in the prior quarter.
  • Over the last five years, Interest Expenses for IONS hit a ceiling of $4.8 million in Q4 2025 and a floor of $1.6 million in Q1 2023.
  • Median Interest Expenses over the past 5 years was $3.3 million (2021), compared with a mean of $3.2 million.
  • Peak annual rise in Interest Expenses hit 163.32% in 2023, while the deepest fall reached 24.22% in 2023.
  • Ionis Pharmaceuticals' Interest Expenses stood at $2.2 million in 2021, then dropped by 22.65% to $1.7 million in 2022, then skyrocketed by 163.32% to $4.6 million in 2023, then decreased by 8.05% to $4.2 million in 2024, then increased by 15.2% to $4.8 million in 2025.
  • The last three reported values for Interest Expenses were $4.8 million (Q4 2025), $4.2 million (Q3 2025), and $4.1 million (Q2 2025) per Business Quant data.